deltatrials
Unknown PHASE2 NCT04884906

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

A Single-arm, Single-center, Open, Prospective Phase II Clinical Study of Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Sponsor: Tianjin Medical University Cancer Institute and Hospital

Conditions Locally Advanced Cervical Cancer
Interventions Albumin Paclitaxel Camrelizumab Cisplatin radiotherapy
Updated 4 times since 2021 Last updated: May 12, 2021 Started: Nov 1, 2020 Primary completion: Nov 1, 2022 Completion: Nov 1, 2024

This PHASE2 trial investigates Locally Advanced Cervical Cancer and is currently ongoing. Tianjin Medical University Cancer Institute and Hospital leads this study, which shows 4 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

4 versions recorded

  1. Dec 2024 — Present [monthly]

    Unknown PHASE2

    Status: Recruiting → Unknown

  2. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  4. Jun 2021 — Jul 2024 [monthly]

    Recruiting PHASE2

    First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Tianjin Medical University Cancer Institute and Hospital
Data source: Tianjin Medical University Cancer Institute and Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Tianjin, China